Results 41 to 50 of about 61,606 (299)

“Intrapericardial Approach” for Venous Outflow Reconstruction in Living‐Donor Liver Transplantation for Budd‐Chiari Syndrome: Surgical Techniques and LongTerm Outcomes

Annals of Gastroenterological Surgery, EarlyView.
Unlike deceased‐donor liver transplantation, living‐donor liver transplantation (LDLT) for Budd‐Chiari Syndrome (BCS) presents distinctive challenges in hepatic venous (HV)‐outflow reconstruction because diseased HV–inferior vena cava (IVC) cannot be entirely replaced with healthy donor vessels.
Koichiro Hata, Tetsuya Tajima, Satoshi Ogiso, Shinji Uemoto, Etsuro Hatano   +4 more
wiley   +1 more source

Nitric Oxide Mediation in Hydroxyurea and Nitric Oxide Metabolites’ Inhibition of Erythroid Progenitor Growth

Biomolecules, 2021
In several systems, hydroxyurea has been shown to trigger nitric oxide (NO) release or activation of NO synthase (NOS). To elucidate this duality in its pharmacological effects, during myelosuppression, we individually examined hydroxyurea’s (NO ...
Tijana Subotički, Olivera Mitrović Ajtić, Dragoslava Djikić, Marijana Kovačić, Juan F. Santibanez, Milica Tošić, Vladan P. Čokić   +6 more
doaj   +1 more source

MRE11 facilitates the removal of human topoisomerase II complexes from genomic DNA [PDF]

, 2012
Topoisomerase II creates a double-strand break intermediate with topoisomerase covalently coupled to the DNA via a 5'-phosphotyrosyl bond. These intermediate complexes can become cytotoxic protein-DNA adducts and DSB repair at these lesions requires ...
Austin, Caroline, Cockell, Simon, Cowell, Ian, Curtis, Hannah, Jackson, Graham, Lee, Ka Cheong, Moiani, Davide, Morris, Nicholas, Padget, Kay, Sondka, Zbyslaw, Tainer, John   +10 more
core   +3 more sources

Iron Chelation Reduces DNA Damage in Sickle Cell Anemia

Clinical and Applied Thrombosis/Hemostasis, 2021
Sickle cell anemia (SCA) is a blood condition that causes severe pain. One of the therapeutic agents used for the treatment of SCA is hydroxyurea, which reduces the episodes of pain but causes DNA damage to white blood cells. The aim of this study was to
Rawan S. Al-Khateeb, Hanan S. Althagafy, Mohammad Zaki ElAssouli, Dunya A. Nori, Mohammed AlFattani, Salwa A. Al-Najjar, Turki Al Amri, Anwar M. Hashem, Steve Harakeh, Nawal Helmi   +9 more
doaj   +1 more source

Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial

JMIR Research Protocols, 2021
BackgroundSickle cell anemia (SCA) is a genetic blood disorder that puts children at a risk of serious medical complications, early morbidity and mortality, and high health care utilization.
Hood, Anna M, Strong, Heather, Nwankwo, Cara, Johnson, Yolanda, Peugh, James, Mara, Constance A, Shook, Lisa M, Brinkman, William B, Real, Francis J, Klein, Melissa D, Hackworth, Rogelle, Badawy, Sherif M, Thompson, Alexis A, Raphael, Jean L, Yates, Amber M, Smith-Whitley, Kim, King, Allison A, Calhoun, Cecelia, Creary, Susan E, Piccone, Connie M, Hildenbrand, Aimee K, Reader, Steven K, Neumayr, Lynne, Meier, Emily R, Sobota, Amy E, Rana, Sohail, Britto, Maria, Saving, Kay L, Treadwell, Marsha, Quinn, Charles T, Ware, Russell E, Crosby, Lori E   +31 more
doaj   +1 more source

A Novel Plasma Heme Assay Reveals Disease Severity in Beta‐Thalassemia and Sickle Cell Anemia

American Journal of Hematology, EarlyView.
ABSTRACT Anemia results from imbalanced hemoglobin or red blood cell production and clearance. Hemolytic anemia, caused by premature red blood cell removal, can be intravascular (in blood) or extravascular (erythrophagocytosis). Hemolysis is common in Sickle Cell Disease (SCD) and Beta‐Thalassemia anemia (β‐thalassemia), the most prevalent inherited ...
Laurent Kiger, Nicolas Hebert, Laura Bencheikh, Vincent Malcor Deydier de Pierrefeu, Anne‐Laure Pham Hung d’Alexandry d’Orengiani, Sandia Adypagavane, Meghan Perkins, Laura Matabishi‐Bibi, France Pirenne, Claire Berquet, Stephane Moutereau, Serge Pissard, Frédéric Galactéros, Michael C. Marden, Pablo Bartolucci   +14 more
wiley   +1 more source

Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia

Trials, 2020
Background Sickle cell disease (SCD) is a severe and devastating hematological disorder that affects over 100,000 persons in the USA and millions worldwide.
Emily R. Meier, Susan E. Creary, Matthew M. Heeney, Min Dong, Abena O. Appiah-Kubi, Stephen C. Nelson, Omar Niss, Connie Piccone, Maa-Ohui Quarmyne, Charles T. Quinn, Kay L. Saving, John P. Scott, Ravi Talati, Teresa S. Latham, Amanda Pfeiffer, Lisa M. Shook, Alexander A. Vinks, Adam Lane, Patrick T. McGann   +18 more
doaj   +1 more source

Widespread Natural Occurrence of Hydroxyurea in Animals. [PDF]

PLoS ONE, 2015
Here we report the widespread natural occurrence of a known antibiotic and antineoplastic compound, hydroxyurea in animals from many taxonomic groups.
David I Fraser, Kyle T Liu, Bryan J Reid, Emily Hawkins, Andrew Sevier, Michelle Pyle, Jacob W Robinson, Pierre H R Ouellette, James S Ballantyne   +8 more
doaj   +1 more source

Drugs for preventing red blood cell dehydration in people with sickle cell disease. [PDF]

, 2018
BACKGROUND: Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells. These are rigid and may block blood vessels leading to acute painful crises and other complications.
Ballas, Samir K., Nagalla, Srikanth
core   +1 more source

RNase H enables efficient repair of R-loop induced DNA damage. [PDF]

, 2016
R-loops, three-stranded structures that form when transcripts hybridize to chromosomal DNA, are potent agents of genome instability. This instability has been explained by the ability of R-loops to induce DNA damage. Here, we show that persistent R-loops
Amon, Jeremy D, Koshland, Douglas
core   +1 more source